Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

The primary catalyst for Rumble is a large, multi-year compute deal with a mystery client, which has fueled speculation that the company is transitioning into a significant player in the AI infrastructure space. While bulls are excited about the potential for a short squeeze and long-term growth driven by this partnership, bears remain skeptical, citing concerns over potential dilution, financing needs, and the lack of official details regarding the deal.

Traders are intensely debating the impact of Executive Chair Larry Ellison's decision to cancel his planned $7.5 billion stock sale, with bulls viewing the reversal as a strong signal of confidence and a potential catalyst for a short squeeze, while bears remain focused on the company's significant capital expenditure requirements and broader AI sector concerns.

The Breakwave Tanker Shipping ETF is trending due to record-high crude tanker freight rates driven by persistent geopolitical instability, specifically ongoing disruptions and conflict surrounding the Strait of Hormuz. Traders remain divided on the sustainability of the price surge, with many debating the optimal timing to short the asset while others view it as a primary hedge against continued global shipping volatility.

Traders are actively debating the market's direction, with many utilizing SQQQ as a hedge against concerns over geopolitical tensions, potential inflation, and perceived overvaluation in the tech and AI sectors. While some investors are betting on a major market correction, others express frustration with intraday volatility and manipulation, leading to a highly fragmented sentiment regarding the best strategy for the current environment.

Summit Therapeutics is trending as traders focus on upcoming clinical trial data readouts and the November FDA PDUFA date for ivonescimab, which the community hopes will demonstrate superiority over current standards of care. Investors remain highly attentive to ongoing insider buying, significant short interest, and competing viewpoints regarding the drug's regulatory pathway and potential for market displacement.

Applied Digital is experiencing volatility amid broader AI infrastructure sector uncertainty and investor apprehension regarding high interest rates, though bullish sentiment persists based on the company's significant contracted data center backlog. The conversation remains polarized between traders tracking technical support levels and those anticipating upcoming financing or lease announcements as critical catalysts for a breakout.

Western Digital shares are facing significant downward pressure following their latest earnings report, despite the company beating revenue and guidance expectations. Traders are expressing frustration over the volatile price action and broader sector sell-off, with many debating whether this represents a temporary overreaction or the cooling of the AI-driven memory supercycle.

Oklo is facing selling pressure and hitting 52-week lows following the announcement of a new $1 billion at-the-market share offering, which has reignited concerns among traders regarding shareholder dilution. While some investors remain bullish on the long-term potential of the company's advanced nuclear reactor technology and institutional interest, others are skeptical due to the lack of commercial revenue, consistent insider selling, and the ongoing dilutive financing model.

The United States Oil Fund is trending as traders focus on the expiration of a ceasefire memorandum with Iran, with rising tensions in the Strait of Hormuz fueling concerns over global oil supply disruptions. Market participants are debating the potential for further crude price volatility, with many monitoring geopolitical headlines and inflation pressures as primary catalysts for the asset's performance.

Viking Therapeutics is seeing increased activity as investors anticipate maintenance dosing data for VK2735, with many looking for signs of competitive efficacy against existing GLP-1 treatments ahead of upcoming healthcare conferences. Discussion remains divided between long-term bulls betting on a potential buyout or partnership and bears focusing on management's communication style, equity offerings, and the timeline to commercialization.